1-4 of 4
Gloria H. Y. Lin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Steven M. Horwitz, James M. Foran, Michael Maris, Jennifer Kimberly Lue, Ahmed Sawas, Craig Okada, Tatyana A. Feldman, Lubomir Sokol, Matthew Mei, Ian W. Flinn, Diego Villa, Mary-Elizabeth M. Percival, Deepa Jagadeesh, Kerry J. Savage, Oleg Akilov, Catherine S. Diefenbach, Youn H. Kim, Gloria H. Y. Lin, Tina Catalano, Penka S. Petrova, Bob Uger, Naomi Molloy, Kathleen Large, Ingmar Bruns, Stephen M. Ansell
Journal: Blood
Blood (2021) 138 (Supplement 1): 2448.
https://doi.org/10.1182/blood-2021-154490
Published: 2021
Journal Articles

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, Jeffrey A. Zonder, Dahlia Sano, Michael Maris, Alexander Lesokhin, Gottfried von Keudell, Catherine Lai, Rod Ramchandren, Tina Catalano, Gloria H. Y. Lin, Bob Uger, Penka S. Petrova, Naomi Molloy, Ingmar Bruns, Swaminathan P Iyer
Journal: Blood
Blood (2021) 138 (Supplement 1): 3560.
https://doi.org/10.1182/blood-2021-153683
Published: 2021
Journal Articles

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, MD, Radhakrishnan Ramchandren, MD, Michael Maris, MD, Alexander M. Lesokhin, MD, Gottfried R. von Keudell, MD PhD, Bruce D. Cheson, MD, Jeff Zonder, MD, Erlene K. Seymour, MD, Tina Catalano, MSc, Gloria H. Y. Lin, PhD, Bob Uger, PhD, Penka S. Petrova, PhD, Kathleen Roberge, ANP, MSc, Yaping Shou, MDPhD, Swami P. Iyer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-136607
Published: 2020
Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Steven M. Horwitz, MD, James M. Foran, MD, Michael Maris, MD, Ahmed Sawas, MD, Craig Okada, MD PhD, Tatyana A. Feldman, MD, Mark D. Minden, Lubomir Sokol, MD PhD, Matthew Mei, MD, Ian W. Flinn, MD PhD, Diego Villa, MDMPH, Mary-Elizabeth M. Percival, MD, Deepa Jagadeesh, MDMPH, Kerry J. Savage, MDMSc, Oleg E. Akilov, MD PhD, Catherine Diefenbach, MD, Youn H. Kim, MD, Gloria H. Y. Lin, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Bob Uger, PhD, Naomi Molloy, BSc, Kathleen Large, RN, MSN, Yaping Shou, MDPhD, Stephen M. Ansell, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–43.
https://doi.org/10.1182/blood-2020-136198
Published: 2020